- Home
- ECO vs CDNA Comparison
ECO vs CDNA Comparison
Compare ECO & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECO
- CDNA
- Stock Information
- Founded
- ECO 2018
- CDNA 1998
- Country
- ECO Greece
- CDNA United States
- Employees
- ECO N/A
- CDNA N/A
- Industry
- ECO
- CDNA Medical Specialities
- Sector
- ECO
- CDNA Health Care
- Exchange
- ECO Nasdaq
- CDNA Nasdaq
- Market Cap
- ECO 800.0M
- CDNA 1.0B
- IPO Year
- ECO N/A
- CDNA 2014
- Fundamental
- Price
- ECO $23.19
- CDNA $19.24
- Analyst Decision
- ECO Strong Buy
- CDNA Buy
- Analyst Count
- ECO 1
- CDNA 6
- Target Price
- ECO $40.00
- CDNA $30.33
- AVG Volume (30 Days)
- ECO 142.5K
- CDNA 929.2K
- Earning Date
- ECO 08-08-2025
- CDNA 07-30-2025
- Dividend Yield
- ECO 9.57%
- CDNA N/A
- EPS Growth
- ECO N/A
- CDNA N/A
- EPS
- ECO 2.48
- CDNA 1.07
- Revenue
- ECO $362,254,143.00
- CDNA $346,421,000.00
- Revenue This Year
- ECO N/A
- CDNA $13.31
- Revenue Next Year
- ECO $3.94
- CDNA $15.46
- P/E Ratio
- ECO $9.35
- CDNA $17.87
- Revenue Growth
- ECO N/A
- CDNA 25.92
- 52 Week Low
- ECO $17.91
- CDNA $14.09
- 52 Week High
- ECO $35.64
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- ECO 53.56
- CDNA 54.70
- Support Level
- ECO $21.27
- CDNA $18.57
- Resistance Level
- ECO $24.46
- CDNA $19.84
- Average True Range (ATR)
- ECO 0.63
- CDNA 0.77
- MACD
- ECO -0.05
- CDNA -0.06
- Stochastic Oscillator
- ECO 59.26
- CDNA 60.53
About ECO Okeanis Eco Tankers Corp.
Okeanis Eco Tankers Corp owns and operates tanker vessels in Greece. The business of the company is to own, charter out, and operate tanker vessels. The company owns, through its vessel-owning subsidiaries, a fleet of around seven tanker vessels and has around eight tanker vessels on order. The sailing fleet consists of around six modern Suezmax tankers and eight VLCC tankers.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.